Status:
COMPLETED
Use of DwI-MR to Predict Chemotherapy Response of Liver Metastases and Hepatocarcinoma
Lead Sponsor:
Stefano Colagrande
Collaborating Sponsors:
Società Italiana Radiologia Medica SIRM
Treviso cà Foncello Hospital
Conditions:
Liver Metastases
Hepatocarcinoma
Eligibility:
All Genders
18-80 years
Brief Summary
One of the most recent and interesting field of diagnostic imaging is diffusion-weighted MR imaging (DW-MRI). Various studies evaluated the application of DW-MRI to diffuse liver disease and focal liv...
Detailed Description
In R patients an increase of the mean diameter of the neoplastic cells should be present from the first week of CHT with a consequent reduction of the ADC-value. Then, the ADC-value should increase af...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- of age, compliant, patients enrolled for CHT, without major contraindications to the MR examination;
- non-confluent liver metastases, from every primary carcinoma histotype biopsy/surgical-proven, without intralesional necrosis/calcification involving \>30% of their volume;
- at least one marker lesion allowing reproducible ADC measurements, i.e. placed at the level of the lower right liver segments;
- multiple confluent hepatocellular carcinomas, histotype biopsy/surgical-proven in prevision of treatment with Sorafenib;
- detection/enrolment by contrast-enhanced CT before CHT that allow to define the lesion size or the gross parenchymal involvement (if HCC)
- Each patient will sign an informed consent, after the procedure will be completely explained.
- For the metastasis: Three diameter of each marker lesion will be measured, and the mean/minimal/maximal ADC±standard deviation will be quantified by region-of-interests (ROIs) placed within the lesion avoiding lesion margins and the necrotic/intratumoral calcification areas.
- For the hepatocarcinoma: Three diameter of gross parenchymal involvement will be measured, and the mean/minimal/maximal ADC±standard deviation will be quantified by large region-of-interests (ROIs) placed within the the lobe containing the involvement.
- All measurements will be repeated for three times even at the level of the adjacent liver parenchyma (within 3 cm from the lesion margins, keeping a ROI diameter \>2 cm). Consequently, the absolute values (s/mm2) of ADC, and the ADC percentages vs. the adjacent liver parenchyma measured at the different times will be compared.
Exclusion
Key Trial Info
Start Date :
February 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2013
Estimated Enrollment :
57 Patients enrolled
Trial Details
Trial ID
NCT01411579
Start Date
February 1 2011
End Date
February 1 2013
Last Update
December 10 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stefano Colagrande
Florence, Italy, Italy, 50134